TD Cowen lowered the firm’s price target on Amgen to $360 from $370 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 earnings based on their sales/scrip trackers and to better align estimates with Q1 and 2024 sales and operating expenses guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Early notable gainers among liquid option names on April 11th
- Amgen shares worth $240-$250 without obesity pipeline, says JPMorgan
- AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
- Amgen upgraded to Conviction Buy from Buy at Goldman Sachs
- Jefferies biotechnology analyst to hold an analyst/industry conference call
